{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:46:32Z","timestamp":1777927592639,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Integrase strand transfer inhibitor (INSTI)-based regimens, such as dolutegravir\/lamivudine\/abacavir (DTG\/3TC\/ABC) and bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF), are recommended as first-line antiretroviral therapy (ART) for people living with HIV (PLH). This study compares their efficacy and safety in ART-na\u00efve men living with HIV (MLH) in a real-world setting over 48 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, randomized clinical trial (February 2021\u2013October 2024) at Hospital de Infectolog\u00eda \u201cLa Raza\u201d enrolled ART-na\u00efve MLH with HIV-1 RNA \u2265500 copies\/mL and creatinine clearance &gt;30\u00a0mL\/min. Participants were randomized 1:1 to BIC\/FTC\/TAF or DTG\/3TC\/ABC. The primary endpoint was undetectable viral load (&lt;50 copies\/mL) at week 48, with safety assessed by adverse events (AEs) per DAIDS criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 311 participants, 153 received BIC\/FTC\/TAF and 158 DTG\/3TC\/ABC. Virologic suppression was achieved in 90% of the BIC\/FTC\/TAF group and 86% of the DTG\/3TCC\/ABC group (p = 0.32). Median CD4+ counts were 649 cells\/\u00b5L (BIC\/FTC\/TAF) and 723 cells\/\u00b5L (DTG\/3\u00a0TC\/ABC) (p = 0.18). DTG\/3TC\/ABC had higher gastrointestinal AEs (21.5% vs 14.3%; p = 0.04) and grade 3 neuropsychiatric AEs. BIC\/FTC\/TAF showed higher insomnia rates. Abacavir-related hypersensitivity occurred in 0.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both regimens showed high efficacy. BIC\/FTC\/TAF was more effective in patients with low baseline CD4 + counts, while DTG\/3TC\/ABC performed better with higher viral loads. DTG\/3TC\/ABC had more neuropsychiatric AEs and rare hypersensitivity reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624251396720","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:59:20Z","timestamp":1763459960000},"page":"363-370","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of dolutegravir\/lamivudine\/abacavir versus bictegravir\/emtricitabine\/tenofovir alafenamide as first-line regimens in real-world settings (MICTLAN study)"],"prefix":"10.1177","volume":"37","author":[{"given":"Jos\u00e9 Antonio","family":"Mata-Mar\u00edn","sequence":"first","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-4003","authenticated-orcid":false,"given":"Mara Soraya","family":"Rodr\u00edguez-Evaristo","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-746X","authenticated-orcid":false,"given":"Ana Luz","family":"Cano-D\u00edaz","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Rosario","family":"Valenzuela-Salazar","sequence":"additional","affiliation":[{"name":"HIV Clinic Department, Outpatient Centers for the Prevention and Care of AIDS and Sexually Transmitted Infections (CAPASITS), Durango"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Chaparro-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Triana-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Hern\u00e1ndez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka Nelly","family":"Pompa-Mera","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0700-2081","authenticated-orcid":false,"given":"Paola Edith","family":"Padilla-Noguera","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Enrique","family":"Gayt\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"MICTLAN study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_3_8_2_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (accessed 06 November 2024)."},{"key":"e_1_3_8_3_2","unstructured":"EACS guidelines version 12.0 October 2023. Guidelines-12.0 PDF. https:\/\/www.eacsociety.org (accessed November 06 2024)."},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01379-9"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/idr15060069"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019896638"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318158a44f"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00544-w"},{"key":"e_1_3_8_18_2","unstructured":"DAIDS Adverse Event Grading Tables | DAIDS Regulatory Support Center (RSC). https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1698946"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105653"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"issue":"4","key":"e_1_3_8_24_2","first-page":"1137","article-title":"Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-Infected patients: a case-control study","volume":"72","author":"Madelain V","year":"2017","unstructured":"Madelain V, Le MP, Champenois K, et al. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-Infected patients: a case-control study. J Antimicrob Chemother 2017; 72(4): 1137\u20131146.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"e_1_3_8_25_2","first-page":"e261","article-title":"Obesity and metabolic complications in people living with HIV","volume":"71","author":"Lake JE","year":"2020","unstructured":"Lake JE, Stanley TL, Apovian CM, et al. Obesity and metabolic complications in people living with HIV. Clin Infect Dis 2020; 71(8): e261\u2013e268.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_3_8_27_2","first-page":"156","article-title":"Late presentation of HIV infection in the era of highly active antiretroviral therapy: a retrospective cohort study in Latin America","volume":"92","author":"Carrazco I","year":"2020","unstructured":"Carrazco I, Romero D, Mac\u00edas J, et al. Late presentation of HIV infection in the era of highly active antiretroviral therapy: a retrospective cohort study in Latin America. Int J Infect Dis 2020; 92: 156\u2013162.","journal-title":"Int J Infect Dis"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16071083"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2023.2203914"},{"issue":"1","key":"e_1_3_8_30_2","first-page":"e0210956","article-title":"Adherence to antiretroviral therapy in resource-limited settings: a systematic review of qualitative findings","volume":"14","author":"Altice F","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, et al. Adherence to antiretroviral therapy in resource-limited settings: a systematic review of qualitative findings. PLoS One 2019; 14(1): e0210956.","journal-title":"PLoS One"},{"issue":"9","key":"e_1_3_8_31_2","first-page":"e408","article-title":"Social determinants of health and HIV treatment outcomes in Latin America: a systematic review","volume":"4","author":"Tucker JD","year":"2017","unstructured":"Tucker JD, Tso LS, Padilla M, et al. Social determinants of health and HIV treatment outcomes in Latin America: a systematic review. Lancet HIV 2017; 4(9): e408\u2013e417.","journal-title":"Lancet HIV"},{"key":"e_1_3_8_32_2","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 2024 fact sheet. Available at: https:\/\/www.unaids.org\/en\/resources\/fact-sheet. (accessed 06 November 2024)."},{"issue":"6","key":"e_1_3_8_33_2","first-page":"e334","article-title":"Tenofovir alafenamide and weight gain in African cohorts: a prospective study","volume":"8","author":"Venter WDF","year":"2021","unstructured":"Venter WDF, Moorhouse M, Sokhela D, et al. Tenofovir alafenamide and weight gain in African cohorts: a prospective study. Lancet HIV 2021; 8(6): e334\u2013e341.","journal-title":"Lancet HIV"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290445"},{"issue":"12","key":"e_1_3_8_35_2","first-page":"2041","article-title":"Cost-effectiveness of newer antiretroviral regimens in treatment-na\u00efve adults with HIV infection","volume":"68","author":"Walensky RP","year":"2019","unstructured":"Walensky RP, Horn T, Piwowar-Manning E, et al. Cost-effectiveness of newer antiretroviral regimens in treatment-na\u00efve adults with HIV infection. Clin Infect Dis 2019; 68(12): 2041\u20132049.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"e_1_3_8_36_2","first-page":"929","article-title":"The impact of community-based adherence support on antiretroviral therapy outcomes: a global perspective","volume":"34","author":"Mills AM","year":"2020","unstructured":"Mills AM, Brunet L, Fusco JS, et al. The impact of community-based adherence support on antiretroviral therapy outcomes: a global perspective. AIDS 2020; 34(6): 929\u2013938.","journal-title":"AIDS"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251396720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624251396720","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624251396720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:47:20Z","timestamp":1777675640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624251396720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/09564624251396720"],"URL":"https:\/\/doi.org\/10.1177\/09564624251396720","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}